Srinivas Gunukula
Cardiovascular Disease · Mesquite, TXNPI 1104896844
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (60.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Philips North America LLC at 39.2% of the total. Reporting peaked in 2019 at $3,800 and has fallen 98.9% since, to $43 in 2023.
Across 168 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$2K
- Amarin Pharma, Inc.$520
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$428
- AstraZeneca$395
- Boston Scientific$376
- Amgen$281
- plus $1K from 17 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$3K
What the payments were for
- Travel & lodging$1,78834%
- Food & beverage$3,13160%
- Education$3006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 14 | $2,048 |
| Amarin Pharma, Inc. | 27 | $520 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $428 |
| AstraZeneca | 17 | $395 |
| Boston Scientific | 11 | $376 |
| Amgen | 21 | $281 |
| Astellas Pharma US Inc | 4 | $231 |
| Abbott | 4 | $155 |
| Medtronic(2 entities) | 6 | $135 |
| E.r. Squibb & Sons, L.L.C. | 8 | $116 |
| Johnson & Johnson | 5 | $78 |
| Novartis | 5 | $74 |
| Cardinal Health 200 LLC | 1 | $68 |
| Merck | 4 | $63 |
| Boehringer Ingelheim | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Tactile Systems Technology Inc | 3 | $35 |
| Edwards Lifesciences | 2 | $26 |
| ZOLL Circulation Inc | 1 | $19 |
| Pfizer | 1 | $19 |
| G Medical Diagnostic Services, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT D Peripheral$1,333
- IGT Device Undivided$590
- Vascepa$102
- CROSSBOSS$102
How this compares
$5,219 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Mesquite
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.